Stock analysts at Chardan Capital started coverage on shares of Unity Biotechnology (NASDAQ:UBX – Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The firm ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...

Unity Biotechnology, Inc. (NASDAQ:UBX – Get Free Report) was down 26.5% during trading on Wednesday . The stock traded as low as $1.24 and last traded at $1.33. Approximately 457,354 shares were ...

NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech ...

UNITY Biotechnology (UBX) strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical ...

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic ...

Given this risk, we thought we'd take a look at whether Unity Biotechnology (NASDAQ:UBX) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn ...

(RTTNews) - Shares of Unity Biotechnology, Inc. (UBX) are gaining 9% in the pre-market trading after it has announced the appointment of Federico Grossi as Chief Medical Officer. Federico Grossi ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...